Regional alterations in the endocannabinoid system in an animal model of depression: Effects of concurrent antidepressant treatment

Journal of Neurochemistry

Volumn 106, Issue 6, 2008, Pages 2322-2336

  Hill, Matthew N ^a   Carrier, Erica J ^b   McLaughlin, Ryan J ^a   Morrish, Anna C ^a   Meier, Sarah E ^b   Hillard, Cecilia J ^b   Gorzalka, Boris B ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

2 Arachidonoylglycerol; Anhedonia; Cannabinoid; Depression; Glucocorticoid; Hypothalamic pituitary adrenal axis

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; ANTIDEPRESSANT AGENT; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; IMIPRAMINE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CHRONIC STRESS; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HIPPOCAMPUS; HYPOTHALAMUS; MALE; MESENCEPHALON; MOTIVATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

ANALGESICS; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ARACHIDONIC ACIDS; BRAIN; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; IMIPRAMINE; MALE; MOTIVATION; POLYUNSATURATED ALKAMIDES; RATS; RATS, LONG-EVANS; RECEPTOR, CANNABINOID, CB1; SEXUAL BEHAVIOR, ANIMAL; STRESS, PSYCHOLOGICAL;

ANIMALIA; RATTUS;

EID: 50849142856     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05567.x     Document Type: Article

References (98)

1. Bambico F. R., Katz N., Debonnel G. Gobbi G. (2007) Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J. Neurosci. 27, 11700 11711.
2. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J. A., Fernandez-Ruiz J. J. Di Marzo V. (1999) Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 256, 377 380.
3. Bortolato M., Mangieri R. A., Fu J. et al. (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol. Psychiatry 62, 1103 1110.
4. Bovasso G. B. (2001) Cannabis abuse is a risk factor for depressive symptoms. Am. J. Psychiatry 158, 2033 2037.
5. Brody A. L., Barsom M. W., Bota R. G. Saxena S. (2001) Prefrontal-subcortical and limbic circuit mediation of major depressive disorder. Semin. Clin. Neuropsychiatry 6, 102 112.
6. Brotto L. A., Gorzalka B. B. LaMarre A. K. (2001) Melatonin protects against the effects of chronic stress on sexual behaviour in male rats. Neuroreport 12, 3465 3469.
7. Caille S., Alvarez-Jaimes L., Polis I., Stouffer D. G. Parsons L. H. (2007) Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J. Neurosci. 27, 3695 3702.
8. Carney R. M., Freedland K. E., Miller G. E. Jaffe A. S. (2002) Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J. Psychosomatic Res. 53, 897 902.
9. Chen C. Bazan N. G. (2005) Lipid signaling: sleep, synaptic plasticity, and neuroprotection. Prostaglandins Other Lipid Mediat. 77, 65 76.
10. Chevaleyre V., Takahashi K. A. Castillo P. E. (2006) Endocannabinoid- mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 29, 37 76.
11. Cota D., Marsicano G., Tschop M. et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423 431.
12. Cota D., Steiner M. A., Marsicano G. et al. (2007) Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary- adrenal axis function. Endocrinology 148, 1574 1581.
13. Degenhardt L., Hall W. Lynskey M. (2003) Exploring the association between cannabis use and depression. Addiction 98, 1493 1504.
14. Deuschle M., Hamann B., Meichel C., Krumm B., Lederbogen F., Kniest A., Colla M. Heuser I. (2003) Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations. J. Clin. Psychiatry 23, 201 205.
15. Devane W. A., Hanus L., Breuer A. et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946 1949.
16. Duman R. S. Monteggia L. M. (2006) A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59, 1116 1127.
17. Duncan G. E., Knapp D. J., Johnson K. B. Breese G. R. (1996) Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. J. Pharmacol. Exp. Ther. 277, 1076 1089.
18. Egertova M., Cravatt B. F. Elphick M. R. (2003) Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119, 481 496.
19. Filip M., Frankowska M., Wydra K., Nowak E. McCreary A. C. (2006) Effects of combined administration of a selective inhibitor of FAAH (URB597) and imipramine or citalopram in the forced swimming test in rats. Eur. Neuropsychopharmacol. 16, S341.
20. Forbes N. F., Stewart C. A., Matthews K. Reid I. C. (1996) Chronic mild stress and sucrose consumption: validity as a model of depression. Physiol. Behav. 60, 1481 1484.
21. Freund T. F., Katona I. Piomelli D. (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83, 1017 1066.
22. Gobbi G., Bambico F. R., Mangieri R. et al. (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl Acad. Sci. USA 102, 18620 18625.
23. Gorzalka B. B., Hill M. N. Hillard C. J. (2008) Regulation of endocannabinoid signaling by stress: implications for affective disorders. Neurosci. Biobehav. Rev. 32, 1152 1160.
24. Greden J. F., Gardner R., King D., Grunhaus L., Carroll B. J. Kronfol Z. (1983) Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. Arch. Gen. Psychiatry 40, 493 500.
25. Griebel G., Stemmelin J. Scatton B. (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57, 261 267.
26. Hansson A. C., Bermudez-Silva F. J., Malinen H. et al. (2007) Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology 32, 117 126.
27. Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., de Costa B. R. Rice K. C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563 583.
28. Herman J. P., Adams D. Prewitt C. (1995) Regulatory changes in neuroendocrine stress-integrative circuitry produced by a variable stress paradigm. Neuroendocrinology 61, 180 190.
29. Hill M. N. Gorzalka B. B. (2004) Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur. J. Pharmacol. 499, 291 295.
30. Hill M. N. Gorzalka B. B. (2005a) Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav. Pharmacol. 16, 333 352.
31. Hill M. N. Gorzalka B. B. (2005b) Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur. Neuropsychopharmacol. 15, 593 599.
32. Hill M. N., Patel S., Carrier E. J., Rademacher D. J., Ormerod B. K., Hillard C. J. Gorzalka B. B. (2005) Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30, 508 515.
33. Hill M. N., Ho W. S., Sinopoli K. J., Viau V., Hillard C. J. Gorzalka B. B. (2006) Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 31, 2591 2599.
34. Hill M. N., Barr A. M., Ho W. S., Carrier E. J., Gorzalka B. B. Hillard C. J. (2007a) Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. J. Neurochem. 103, 47 56.
35. Hill M. N., Karacabeyli E. S. Gorzalka B. B. (2007b) Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 32, 350 357.
36. 1 receptor density in the hippocampus. Hippocampus 18, 221 226.
37. Hill M. N., Miller G. E., Ho W. S., Gorzalka B. B. Hillard C. J. (2008b) Serum endocannabinoid content is altered in females with depressive disorders: a preliminary study. Pharmacopsychiatry 41, 48 53.
38. Hillard C. J. (2000a) Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat. 61, 3 18.
39. Hillard C. J. (2000b) Endocannabinoids and vascular function. J. Pharmacol. Exp. Ther. 294, 27 32.
40. Hillard C. J., Edgemond W. S. Campbell W. B. (1995a) Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J. Neurochem. 64, 677 683.
41. Hillard C. J., Wilkison D. M., Edgemond W. S. Campbell W. B. (1995b) Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim. Biophys. Acta 1257, 249 256.
42. Hillard C. J., Hill M. N., Carrier E. J., Shi L., Cullinan W. E. Gorzalka B. B. (2006) Regulation of cannabinoid receptor expression by chronic unpredictable stress in rats and mice. Soc. Neurosci. Abstr. 746.19.
43. Holsboer F. (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23, 477 501.
44. Howlett A. C. (2002) The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 68-69, 619 631.
45. Hungund B. L., Vinod K. Y., Kassir S. A., Basavarajappa B. S., Yalamanchili R., Cooper T. B., Mann J. J. Arango V. (2004) Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol. Psychiatry 9, 184 190.
46. Iredale P. A., Terwilliger R., Widnell K. A., Nestler E. J. Duman R. S. (1996) Differential regulation of corticotropin-releasing factor1 receptor expression by stress and agonist treatments in brain and cultured cells. Mol. Pharmacol. 50, 1103 1110.
47. Kessler R. C., Berglund P., Demler O. et al. (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289, 3095 3105.
48. Kim Y. K., Na K. S., Shin K. H., Jung H. Y., Choi S. H. Kim J. B. (2007) Cytokine imbalance in the pathophysiology of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 1044 1053.
49. Klein T. W., Newton C., Larsen K. et al. (2003) The cannabinoid system and immune modulation. J. Leukoc. Biol. 74, 486 496.
50. 1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder and major depression. J. Neural. Transm. 114, 1055 1063.
51. Kunos G., Jarai Z., Batkai S., Goparaju S. K., Ishac E. J., Liu J., Wang L. Wagner J. A. (2000) Endocannabinoids as cardiovascular modulators. Chem. Phys. Lipids 108, 159 168.
52. Langer S. Z. Schoemaker H. (1988) Effects of antidepressants on monoamine transporters. Prog. Neuropsychopharmacol. Biol. Psychiatry 12, 193 216.
53. Laviolette S. R. Grace A. A. (2005) Cannabinoids potentiate emotional learning plasticity in neurons of the medial prefrontal cortex through basolateral amygdala inputs. J. Neurosci. 26, 6458 6468.
54. Ligresti A., Cascio M. G. Di Marzo V. (2005) Endocannabinoid metabolic pathways and enzymes. Curr. Drug Targets CNS Neurol. Disord. 4, 615 623.
55. Lopez J. F., Chalmers D. T., Little K. Y. Watson S. J. (1998) Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry 43, 547 573.
56. Lynskey M. T., Glowinski A. L., Todorov A. A., Bucholz K. K., Madden P. A., Nelson E. C., Statham D. J., Matin N. G. Heath A. C. (2004) Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch. Gen. Psychiatry 61, 1026 1032.
57. Mahler S. V., Smith K. S. Berridge K. C. (2007) Endocannabinoid hedonic hotspot for sensory pleasure: Anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 32, 2267 2278.
58. Mangieri R. A. Piomelli D. (2007) Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol. Res. 56, 360 366.
59. Marsicano G. Lutz B. (2006) Neuromodulatory functions of the endocannabinoid system. J. Endocrinol. Invest. 29, 27 46.
60. Marsicano G., Wotjak C. T., Azad S. C. et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530 534.
61. Mato S., Aso E., Castro E., Martin M., Valverde O., Maldonado R. Pazos A. (2007) CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A/C receptors. J. Neurochem. 103, 2111 2120.
62. Mayberg H. S. (1997) Limbic-cortical dysregulation: a proposed model of depression. J. Neuropsychiatry Clin. Neurosci. 9, 471 481.
63. McEwen B. S. (2005) Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 54, 20 23.
64. Nestler E. J., Gould E., Manji H. et al. (2002) Preclinical models: status of basic research in depression. Biol. Psychiatry 52, 503 528.
65. O'Neil M. F. Moore N. A. (2003) Animal models of depression: are there any? Hum. Psychopharmacol. 18, 239 254.
66. Oliva J. M., Uriguen L., Perez-Rial S. Manzanares J. (2005) Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain. Neuropharmacology 49, 618 626.
67. 14C] as a substrate for anandamide amidase. Life Sci. 56, 2033 2040.
68. Ossowska G., Nowak G., Kata R., Klenk-Majewska B., Danilczuk Z. Zebrowska-Lupina I. (2001) Brain monoamine receptors in a chronic unpredictable stress model in rats. J. Neural. Transm. 108, 311 319.
69. Ossowska G., Nowak G., Klenk-Majewska B., Danilczuk Z. Zebrowska-Lupina I. (2002) Effect of imipramine on brain D-1 and 5-HT-2A receptors in a chronic unpredictable stress model in rats. Pol. J. Pharmacol. 54, 89 93.
70. Patel S., Rademacher D. J. Hillard C. J. (2003) Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J. Pharmacol. Exp. Ther. 306, 880 888.
71. Patel S., Roelke C. T., Rademacher D. J., Cullinan W. E. Hillard C. J. (2004) Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145, 5431 5438.
72. Patel S., Carrier E. J., Ho W. S., Rademacher D. J., Cunningham S., Reddy D. S., Falck J. R., Cravatt B. F. Hillard C. J. (2005a) The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J. Lipid Res. 46, 342 349.
73. Patel S., Roelke C. T., Rademacher D. J. Hillard C. J. (2005b) Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur. J. Neurosci. 21, 1057 1069.
74. Pazos A., Mostany R., Mato S. et al. (2006) Constitutive activity of cannabinoid CB1 receptors in major depression. Soc. Neurosci. Abstr. 191.18.
75. 1 receptor function and POMC gene expression in the rat brain. Eur. Neuropsychopharmacol. 14, S318.
76. Rademacher D. J. Hillard C. J. (2007) Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 633 641.
77. Ravinet Trillou C., Delgorge C., Menet C., Arnone M. Soubrie P. (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 28, 640 648.
78. Reich C. G., Taylor M. E. McCarthy M. M. (2007) Stress-induced modulation of the endocannabinoid system in the HPA axis: effects of gonadal status. Soc. Neurosci. Abstr. 197.7.
79. Reid I., Forbes N., Stewart C. Matthews K. (1997) Chronic mild stress and depressive disorder: a useful new model? Psychopharmacology 134, 365 367.
80. Ressler K. J. Nemeroff C. B. (2000) Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress. Anxiety 12, 2 19.
81. Ribeiro S. C., Tandon R., Grunhaus L. Greden J. F. (1993) The DST as a predictor of outcome in depression: a meta-analysis. Am. J. Psychiatry 150, 1618 1629.
82. Sanchis-Segura C., Cline B. H., Marsicano G., Lutz B. Spanagel R. (2004) Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology 176, 223 232.
83. Shearman L. P., Rosko K. M., Fleischer R., Wang J., Xu S., Tong X. S. Rocha B. A. (2003) Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav. Pharmacol. 14, 573 582.
84. Steiner M. A., Marsicano G., Nestler E. J., Holsboer F., Lutz B. Wotjak C. T. (2008a) Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 33, 54 67.
85. Steiner M. A., Wanisch K., Monroy K., Marsicano G., Borroni E., Bachli H., Holsboer F., Lutz B. Wotjak C. T. (2008b) Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J. 8, 196 208.
86. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A. Waku K. (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89 97.
87. Tzavara E. T., Davis R. J., Perry K. W., Li X., Salhoff C., Bymaster F. P., Witkin J. M. Nomikos G. G. (2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. 138, 544 553.
88. Uriguen L., Perez-Rial S., Ledent C., Palomo T. Manzanares J. (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmcology 46, 966 973.
89. Valenti M., Vigano D., Casico M. G., Rubino T., Steardo L., Parolaro D. Di Marzo V. (2004) Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cell. Mol. Life Sci. 61, 945 950.
90. Vinod K. Y. Hungund B. L. (2006) Role of the endocannabinoid system in depression and suicide. Trends Pharmacol. Sci. 27, 539 545.
91. Vinod K. Y., Arango V., Xie S., Kassir S. A., Mann J. J., Cooper T. B. Hungund B. L. (2005) Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol. Psychiatry 57, 480 486.
92. Williams K. Reynolds M. F. (2006) Sexual dysfunction in major depression. CNS Spectr. 11, 19 23.
93. Willner P. (2005) Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52, 90 110.
94. Willner P., Towell A., Sampson D., Sophokleous S. Muscat R. (1987) Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 93, 358 364.
95. Willner P., Muscat R. Papp M. (1992) Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci. Biobehav. Rev. 16, 525 534.
96. Witkin J. M., Tzavara E. T., Davis R. J., Li X. Nomikos G. G. (2005) A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharnacol. Sci. 26, 609 617.
97. Wong M. L., Kling M. A., Munson P. J. et al. (2000) Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl Acad. Sci. USA 97, 325 330.
98. Xu Y., Ku B., Cui L., Li X., Barish P. A., Foster T. C. et al. (2007) Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res. 1162, 9 18.